Literature DB >> 7517246

Risperidone for schizophrenia.

J G Edwards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7517246      PMCID： PMC2540264          DOI： 10.1136/bmj.308.6940.1311

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

Review 1.  Risperidone.

Authors:  M G Livingston
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

Review 2.  Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.

Authors:  J M Kane
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Biochemical profile of risperidone, a new antipsychotic.

Authors:  J E Leysen; W Gommeren; A Eens; D de Chaffoy de Courcelles; J C Stoof; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

4.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

5.  Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.

Authors:  D E Addington; B Jones; D Bloom; G Chouinard; G Remington; P Albright
Journal:  Clin Ther       Date:  1993 Sep-Oct       Impact factor: 3.393

6.  Risperidone: clinical safety and efficacy in schizophrenia.

Authors:  R L Borison; A P Pathiraja; B I Diamond; R C Meibach
Journal:  Psychopharmacol Bull       Date:  1992

7.  Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.

Authors:  O J Høyberg; C Fensbo; J Remvig; O Lingjaerde; M Sloth-Nielsen; I Salvesen
Journal:  Acta Psychiatr Scand       Date:  1993-12       Impact factor: 6.392

8.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.

Authors:  A Claus; J Bollen; H De Cuyper; M Eneman; M Malfroid; J Peuskens; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1992-04       Impact factor: 6.392

9.  In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.

Authors:  J E Leysen; P M Janssen; W Gommeren; J Wynants; P J Pauwels; P A Janssen
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

10.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030
View more
  6 in total

1.  Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report.

Authors:  Ankit Patel; Naaz Malek; Fasiha Haq; Lauren Turnbow; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2013

2.  Agranulocytosis and clozapine.

Authors:  V J Dev; T Rosenberg; P Krupp
Journal:  BMJ       Date:  1994-07-02

Review 3.  WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

Authors:  Simon Gilbody; Anne-Marie Bagnall; Lorna Duggan; Arja Tuunainen
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

4.  Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

Review 5.  Estrogen control of central neurotransmission: effect on mood, mental state, and memory.

Authors:  G Fink; B E Sumner; R Rosie; O Grace; J P Quinn
Journal:  Cell Mol Neurobiol       Date:  1996-06       Impact factor: 5.046

6.  Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron-astrocyte-microglia dysregulation.

Authors:  Rigil K Yeung; Zheng-Hua Xiang; Shui-Ying Tsang; Rui Li; Timothy Y C Ho; Qi Li; Chok-King Hui; Pak-Chung Sham; Ming-Qi Qiao; Hong Xue
Journal:  Transl Psychiatry       Date:  2018-07-17       Impact factor: 6.222
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.